TTR and amyloidosis: In contrast with other ASYN‐focused agents in development, UCB0599 binds and stabilizes unfolded ASYN and therefore has a similar approach to that of tafamidis on transthyretin, shown to slow disease progression of hereditary transthyretin amyloidosis.22